Abstract
A bioprocess employing Microbacterium sp. MA 5614 was developed for the production of the MK-0476 ( S)-hydroxy ester by asymmetric bioreduction of the corresponding keto ester. The cysteinyl leukotriene 1 receptor antagonist MK-0476 [3-[(1S)-[3(E)-[2-(7-chloroquinolinyl)ethenyl]phenyl]-3-(acetylphenyl)-propylthiol]-2( S)-methylpropanoic acid] is currently undergoing clinical evaluation for the treatment of asthma. Optimization of the bioconversion medium composition and the time of keto ester addition, as well as the development of a keto ester feeding strategy yielded improvements in the bioreduction rate and final ( S)-hydroxy ester titer, by 20- and 25-fold respectively. This asymmetric bioreduction process supported the production of preparative quantities of ( S)-hydroxy ester with an enantiomeric excess greater than 95%.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
